Zhejiang Hisun Pharmaceutical To Acquire Rights To Rigerna Therapeutics's Tech Platform, Product

What happened

Zhejiang Hisun Pharmaceutical plans to acquire global rights to Rigerna Therapeutics' small nucleic acid technology platform and its RGN6669 product. The deal includes a 10 million yuan upfront payment, plus development milestone payments of up to 348 million yuan and sales milestone payments of up to 630 million yuan.

Confirmed

Global impact / market context

This agreement gives Hisun access to Rigerna's drug technology and a specific product candidate. The structure limits the initial cash outlay to 10 million yuan, while tying larger future payments to development progress and actual sales, which helps share risk between the two companies.

Analyst inference

Pharmaceutical companies often pay small upfront amounts and larger milestone payments to acquire outside technology, which means cash is released only as targets are met. For Hisun, this spreads the cost of building its drug pipeline over time rather than committing the full amount at once.

Analyst inference

What to watch

1. The upfront payment is 10 million yuan, about $1.50 million, while development milestone payments could reach 348 million yuan and sales milestone payments up to 630 million yuan. Confirmed
2. Investors should watch whether Hisun discloses a timetable for the RGN6669 product's development stages, since milestone payments depend on reaching agreed scientific and regulatory targets. Proposed
3. Future sales of RGN6669 will determine whether the larger sales milestone payments are made, so any launch delays or weak demand would reduce the total amount Hisun ultimately pays. Analyst inference

Evidence

• Original source link unavailable